148 related articles for article (PubMed ID: 33367372)
1. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.
Yang M; Xu Z; Yan H; Tsai HI; Su D; Yan F; Lu Q; Feng J; Zeng W; Xi L; Zha H; Ling Y; He C; Wu Y; Xu X; Zheng G; Liu G; Chen H; Cheng F
Biomater Sci; 2021 Feb; 9(4):1246-1255. PubMed ID: 33367372
[TBL] [Abstract][Full Text] [Related]
2. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 targeting can promote allograft survival.
Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
[TBL] [Abstract][Full Text] [Related]
4. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
[TBL] [Abstract][Full Text] [Related]
5. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
[TBL] [Abstract][Full Text] [Related]
6. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer.
Li B; Yang T; Liu J; Yu X; Li X; Qin F; Zheng J; Liang J; Zeng Y; Zhou Z; Liu L; Zhang B; Yao W; Feng Z; Zeng G; Zhou Q; Chen L
Acta Biomater; 2023 Apr; 161():184-200. PubMed ID: 36893957
[TBL] [Abstract][Full Text] [Related]
7. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
8. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
Wang C; Yi T; Qin L; Maldonado RA; von Andrian UH; Kulkarni S; Tellides G; Pober JS
J Clin Invest; 2013 Apr; 123(4):1677-93. PubMed ID: 23478407
[TBL] [Abstract][Full Text] [Related]
11. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
[TBL] [Abstract][Full Text] [Related]
12. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
[TBL] [Abstract][Full Text] [Related]
15. Vascularized composite allograft rejection is delayed by infusion of IFN-γ-conditioned BMSCs through upregulating PD-L1.
Wang Y; Xi Y; Han F; Liu Y; Li N; Ren Z; Xue J; Guo L; Hu D
Cell Tissue Res; 2019 May; 376(2):211-220. PubMed ID: 30613905
[TBL] [Abstract][Full Text] [Related]
16. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.
Zha H; Xu Z; Xu X; Lu X; Shi P; Xiao Y; Tsai HI; Su D; Cheng F; Cheng X; Chen H
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745835
[TBL] [Abstract][Full Text] [Related]
18. Blockade or deficiency of PD-L1 expression in intestinal allograft accelerates graft tissue injury in mice.
Matsushima H; Morita-Nakagawa M; Datta S; Pavicic PG; Hamilton TA; Abu-Elmagd K; Fujiki M; Osman M; D'Amico G; Eguchi S; Hashimoto K
Am J Transplant; 2022 Mar; 22(3):955-965. PubMed ID: 34679256
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR.
Wei Y; Liang M; Xiong L; Su N; Gao X; Jiang Z
Exp Cell Res; 2021 May; 402(2):112575. PubMed ID: 33771483
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 expression in cardiac transplantation.
Bishawi M; Bowles D; Pla MM; Oakes F; Chiang Y; Schroder J; Milano C; Glass C
Cardiovasc Pathol; 2021; 54():107331. PubMed ID: 33737091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
